Biotechnology shares rose throughout the day Friday and remained up following the U.S. House vote and approval of a revised $700 billion rescue package for failing financial companies.

Drug maker Cephalon Inc., completing a previously announced settlement, will pay $425 million for illegally marketing a highly addictive lollipop painkiller and two other drugs for non-approved uses.

Biotechnology shares fell Monday as the market plunged following the U.S. House's rejection of a $700 billion rescue package for failing financial companies.

To give investors an edge, CNBC asked the experts for their best stock picks now.

To give investors an edge, CNBC asked the market experts where investors should be placing their bets now.